Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + atezolizumab in metastatic castration-resistant prostate cancer
NCT04446117Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Exelixis, Inc. Primary endpoints: Progression-Free Survival per RECIST 1.1 by BIRC at 30 months and Overall Survival at 45 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04446117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446117.